Jakafi and Pancreatic carcinoma - a phase IV clinical study of FDA data

Summary:

Pancreatic carcinoma is found among people who take Jakafi, especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Jakafi and have Pancreatic carcinoma. It is created by eHealthMe based on reports of 46,732 people who have side effects when taking Jakafi from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 26, 2022

46,732 people reported to have side effects when taking Jakafi.
Among them, 11 people (0.02%) have Pancreatic carcinoma.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 46,803 Jakafi users for its effectiveness, alternative drugs and more.

What is Pancreatic carcinoma?

Pancreatic carcinoma (pancreatic cancer) is found to be associated with 1,473 drugs and 838 conditions by eHealthMe.

Number of Jakafi and Pancreatic carcinoma reports submitted per year:

Could Jakafi cause Pancreatic carcinoma?

Time on Jakafi when people have Pancreatic carcinoma *:

Gender of people who have Pancreatic carcinoma when taking Jakafi *:

female: 28.57 %
male: 71.43 %

Age of people who have Pancreatic carcinoma when taking Jakafi *:

Common drugs people take besides Jakafi *:

Common side effects people have besides Pancreatic carcinoma *:

Second Primary Malignancy (after getting cure a cancer, a new cancer development): 6 people, 54.55%
Abdominal Pain: 2 people, 18.18%
Metastases To Liver (cancer spreads to liver): 2 people, 18.18%
Anaemia (lack of blood): 2 people, 18.18%
Splenomegaly (enlargement of spleen): 2 people, 18.18%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 9.09%
Breathing Difficulty: 1 person, 9.09%
Gait Disturbance: 1 person, 9.09%
Gallstones (stone formation by bile component): 1 person, 9.09%
Gamma-Glutamyltransferase Increased: 1 person, 9.09%

Common conditions people have *:

Rectal Cancer (cancer of rectum): 1 person, 9.09%
Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 1 person, 9.09%
Leukaemia (blood or bone marrow cancer): 1 person, 9.09%
Cytomegalovirus Infection: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Jakafi and have Pancreatic carcinoma?

Check whether Pancreatic carcinoma is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Pancreatic carcinoma and when was it recovered:

Pancreatic carcinoma in Jakafi

Expand to all the drugs that have ingredients of ruxolitinib phosphate:

Pancreatic carcinoma and drugs with ingredients of ruxolitinib phosphate

Alternative drugs to, pros and cons of Jakafi:

Jakafi (46,803 reports)

Common Jakafi side effects:

Fatigue (feeling of tiredness): 6,000 reports
Death: 4,149 reports
Thrombocytopenia (decrease of platelets in blood): 3,514 reports
Dizziness: 2,922 reports
Weakness: 2,809 reports
Headache (pain in head): 2,604 reports

Browse all side effects of Jakafi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Pancreatic carcinoma treatments and more:

Pancreatic carcinoma (45,845 reports)

COVID vaccines that are related to Pancreatic carcinoma:

Common drugs associated with Pancreatic carcinoma:

How the study uses the data?

The study uses data from the FDA. It is based on ruxolitinib phosphate (the active ingredients of Jakafi) and Jakafi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.